Skip to content
Biodatica
Start free

Seagen, a wholly owned subsidiary of Pfizer

Aurora, Colorado

OncologyADCPhase IIIListed · PFE

This company trades under its own ticker, so it sits outside Biodatica’s pre-ticker window. The record stays here because its filings are real, but the feed leaves listed companies out unless you ask for them.

Sign in to watch

What changed

Phase I trial registered: A Safety Study of PF-08046044/SGN-35C in Adults With Advanced Cancers

1w agoTrial registeredJul 6, 2026Source filing (opens the source filing in a new tab)

Momentum

85no change

Momentum 85 out of 100, unchanged since the last recompute.

Accelerating: several high-weight events landed recently.

Runway (estimate)

—unknown

No disclosed raise on file, so there is nothing to model from.

Stage

Phase III

The furthest-along thing in the public record. Not a projection.

Runway is an estimate: the last disclosed raise (SEC Form D) minus a modeled burn rate for the company’s stage and therapeutic area. It is not a disclosure, and companies routinely raise non-dilutive money we can’t see. How this is calculated.

Grant to raise

Every record Biodatica has resolved onto this company, newest first, each linked to the filing it came from. Where a source publishes no stable deep link for a record, the identifier is shown so you can look it up yourself.

  1. Trial

    PHASE1 registered

    May 28, 2024

    Hodgkin Disease, Lymphoma, T-Cell, Peripheral, Lymphoma, Large B-Cell, Diffuse, Lymphoma, Large-Cell, Anaplastic · TERMINATED · sponsor: Seagen, a wholly owned subsidiary of Pfizer · A Safety Study of PF-08046044/SGN-35C in Adults With Advanced Cancers

    ClinicalTrials.gov · NCT06254495 (opens the source filing in a new tab)

  2. Trial

    PHASE2 registered

    Nov 14, 2023

    Carcinoma, Non-Small-Cell Lung, Ovarian Neoplasms, Endometrial Neoplasms, Head and Neck Neoplasms · ACTIVE_NOT_RECRUITING · sponsor: Seagen, a wholly owned subsidiary of Pfizer · A Study of Disitamab Vedotin in Previously Treated Solid Tumors That Express HER2

    ClinicalTrials.gov · NCT06003231 (opens the source filing in a new tab)

  3. Trial

    PHASE3 registered

    Sep 22, 2023

    Urothelial Carcinoma · ACTIVE_NOT_RECRUITING · sponsor: Seagen, a wholly owned subsidiary of Pfizer · Disitamab Vedotin With Pembrolizumab vs Chemotherapy in Previously Untreated Urothelial Cancer Expressing HER2

    ClinicalTrials.gov · NCT05911295 (opens the source filing in a new tab)

  4. Trial

    PHASE1 registered

    Jan 12, 2022

    Ovarian Neoplasms, Peritoneal Neoplasms, Fallopian Tube Neoplasms, Triple Negative Breast Neoplasms, HER2 Negative Breast Neoplasms, Hormone Receptor Positive Breast Neoplasms, Endometrial Neoplasms, Carcinoma, Non-Small-Cell Lung, Cholangiocarcinoma, Gallbladder Carcinoma, Adenoid Cystic Carcinoma · TERMINATED · sponsor: Seagen, a wholly owned subsidiary of Pfizer · A Study of Felmetatug Vedotin/SGN-B7H4V in Advanced Solid Tumors

    ClinicalTrials.gov · NCT05194072 (opens the source filing in a new tab)

Biodatica publishes impersonal research shown identically to every subscriber. This dossier is informational only, it is not investment advice, and the momentum and runway figures are estimates derived from public filings. The underlying records are U.S. government works. Disclosures · Data sources